Farallon Capital Management LLC Beam Therapeutics Inc. Transaction History

Farallon Capital Management LLC

$23.1 Billion
Q3 2025

A detailed history of Farallon Capital Management LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Farallon Capital Management LLC holds 10,063,111 shares of BEAM stock, worth $222 Million. This represents 1.06% of its overall portfolio holdings.

Number of Shares

10,063,111

Holding current value

$222 Million

% of portfolio

1.06%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$16.01 - $25.1 $800,500 - $1.26 Million	50,000 Added 0.5%	10,063,111 $244 Million
Q2 2025 Aug 14, 2025	BUY	$14.54 - $20.24 $1.24 Million - $1.72 Million	85,000 Added 0.86%	10,013,111 $170 Million
Q1 2025 May 15, 2025	BUY	$19.53 - $34.09 $33 Million - $57.6 Million	1,688,988 Added 20.5%	9,928,111 $194 Million
Q4 2024 Feb 14, 2025	BUY	$21.55 - $30.35 $668,050 - $940,850	31,000 Added 0.38%	8,239,123 $204 Million
Q3 2024 Nov 14, 2024	BUY	$22.57 - $33.14 $6.66 Million - $9.78 Million	295,000 Added 3.73%	8,208,123 $201 Million

Q2 2024 Aug 14, 2024	BUY	$21.22 - $32.66 $72.2 Million - $111 Million	3,401,370 Added 75.39%	7,913,123 $185 Million
Q1 2024 May 15, 2024	BUY	$23.46 - $45.07 $9.52 Million - $18.3 Million	406,000 Added 9.89%	4,511,753 $149 Million
Q4 2023 Feb 14, 2024	BUY	$17.69 - $30.76 $72.6 Million - $126 Million	4,105,753 New	4,105,753 $112 Million
Q3 2023 Nov 14, 2023	BUY	$23.01 - $32.46 $103 Million - $145 Million	4,481,839 New	4,481,839 $108 Million
Q2 2023 Aug 14, 2023	BUY	$29.32 - $35.99 $281,501 - $345,539	9,601 Added 0.28%	3,441,522 $110 Million
Q1 2023 May 15, 2023	BUY	$30.15 - $48.79 $964,800 - $1.56 Million	32,000 Added 0.94%	3,431,921 $105 Million
Q4 2022 Feb 14, 2023	SELL	$36.73 - $51.6 $8.5 Million - $11.9 Million	-231,350 Reduced 6.37%	3,399,921 $133 Million
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $6.33 Million - $11.2 Million	159,000 Added 4.58%	3,631,271 $173 Million
Q2 2022 Aug 15, 2022	BUY	$29.86 - $62.36 $26.2 Million - $54.7 Million	877,884 Added 33.84%	3,472,271 $134 Million
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $17.7 Million - $27.1 Million	329,342 Added 14.54%	2,594,387 $149 Million
Q4 2021 Feb 14, 2022	BUY	$68.02 - $99.06 $37.2 Million - $54.2 Million	547,455 Added 31.87%	2,265,045 $181 Million
Q3 2021 Nov 15, 2021	BUY	$84.37 - $133.6 $18.4 Million - $29.1 Million	217,590 Added 14.51%	1,717,590 $149 Million
Q2 2021 Aug 13, 2021	BUY	$64.12 - $128.71 $58.2 Million - $117 Million	907,519 Added 153.17%	1,500,000 $193 Million
Q1 2021 May 17, 2021	BUY	$71.28 - $120.75 $30.1 Million - $51 Million	422,317 Added 248.18%	592,481 $47.4 Million
Q1 2020 May 15, 2020	BUY	$13.31 - $29.2 $2.26 Million - $4.97 Million	170,164 New	170,164 $3.06 Million

Others Institutions Holding BEAM

# of Institutions

249

Shares Held

95M

Call Options Held

888K

Put Options Held

549K

View Full List

About Beam Therapeutics Inc.

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.55B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

More about BEAM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.

Account

Farallon Capital Management LLC Beam Therapeutics Inc. Transaction History